哈药股份：12月24日召开董事会会议

Group 1 - The core point of the article is that Harbin Pharmaceutical Group Co., Ltd. (哈药股份) held its 22nd meeting of the 10th Board of Directors on December 24, 2025, via telecommunication, where it reviewed proposals including the renaming of the Strategic Decision-Making Committee and amendments to its working rules [1] - For the year 2024, the revenue composition of Harbin Pharmaceutical includes: 36.87% from wholesale medical clients, 16.14% from pharmaceutical industry-health products, 15.87% from chemical preparations, 13.99% from wholesale commercial clients, and 10.46% from retail pharmaceutical commerce [1] - As of the report date, the market capitalization of Harbin Pharmaceutical is 8.9 billion yuan [1] Group 2 - The article also mentions Yang Lingjiang's acquisition of a leading domestic winery, raising questions about whether 1919 will restart its listing process [1] - There is a quote expressing urgency regarding the realization of a 100 billion yuan goal, indicating pressure for performance [1]